MedTrace Logo

Pharmacokinetic Study of Subcutaneous Testosterone Enanthate

NCT02233751 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2019-04-19

Study results available
· View outcomes & findings →

Summary

Evaluation of pharmacokinetics of subcutaneous testosterone enanthate

Conditions

  • Hypogonadism

Interventions

COMBINATION_PRODUCT

Testosterone enanthate auto-injector

Randomization then administration of combination product study medication according to group assignment

Sponsors & Collaborators

  • Antares Pharma Inc.

    lead INDUSTRY

Principal Investigators

  • Jonathan Jaffe, MD · Antares Pharma Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2014-10-31
Completion
2014-10-31
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02233751 on ClinicalTrials.gov